Source: Current Drug Targets. Unidade: FCF
Subjects: TRYPANOSOMA CRUZI, COMPOSTOS HETEROCÍCLICOS, ANTIPROTOZOÁRIOS, DOENÇAS NEGLIGENCIADAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONE, Kamdem Boniface et al. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development. Current Drug Targets, v. 23, n. 1, p. 33-59, 2022Tradução . . Disponível em: https://doi.org/10.2174/1389450122666210412125643. Acesso em: 25 ago. 2024.APA
Pone, K. B., Dalhatou, S., Paumo, H. K., Seru, L. M. K., & Ferreira, E. I. (2022). Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development. Current Drug Targets, 23( 1), 33-59. doi:10.2174/1389450122666210412125643NLM
Pone KB, Dalhatou S, Paumo HK, Seru LMK, Ferreira EI. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development [Internet]. Current Drug Targets. 2022 ; 23( 1): 33-59.[citado 2024 ago. 25 ] Available from: https://doi.org/10.2174/1389450122666210412125643Vancouver
Pone KB, Dalhatou S, Paumo HK, Seru LMK, Ferreira EI. Triazole-containing heterocycles: privileged scaffolds in anti-Trypanosoma cruzi drug development [Internet]. Current Drug Targets. 2022 ; 23( 1): 33-59.[citado 2024 ago. 25 ] Available from: https://doi.org/10.2174/1389450122666210412125643